The Hindu Businessline

Granules India expecting sole first to file status on Ruxolitinib Extended-Release Tablets

If confirmed by the FDA and allapplicable statutory and regulatory requirements are satisfied, first-to-file status may provide eligibility for 180 days of generic drug exclusivity under US law